CATB - Catabasis Pharmaceuticals, Inc.
| Previous Close | 7.41 |
| Open | 7.50 |
| Bid | 0.00 x 900 |
| Ask | 8.49 x 900 |
| Day's Range | 7.21 - 7.51 |
| 52 Week Range | 3.60 - 9.76 |
| Volume | 36,968 |
| Avg. Volume | 91,180 |
| Market Cap | 83.941M |
| Beta (3Y Monthly) | 1.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.56 |
| Earnings Date | Aug 8, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.00 |
- Simply Wall St.•4 days ago
Does Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) CEO Pay Reflect Performance?
Jill Milne became the CEO of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) in 2008. This analysis aims first to...
- Business Wire•22 days ago
Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, shared an update on the clinical development of edasalonexent, a novel NF-kB inhibitor for the treatment of Duchenne muscular dystrophy (DMD) this week at the Parent Project Muscular Dystrophy (PPMD) 25th Annual Conference. Screening is ongoing for the randomized, double-blind, placebo-controlled trial in the United States, Canada, Australia, the United Kingdom, Ireland, Sweden, Germany and Israel and making strong progress. Clinical trial sites globally are enrolling quickly and sites in the United Kingdom, Ireland, Sweden, Germany and Israel are at capacity and no longer accepting additional patients.
- Business Wire•28 days ago
Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today presented new preclinical data showing preserved bone health with edasalonexent in contrast to negative effects of the corticosteroid prednisolone in a mouse model of Duchenne muscular dystrophy (DMD). Edasalonexent is a novel NF-kB inhibitor in Phase 3 development for the treatment of DMD. The data were presented at the Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy.
- Business Wire•last month
Catabasis Pharmaceuticals to Present at Upcoming Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and Parent Project Muscular Dystrophy 25th Annual Conference
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent, a novel NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy , at two upcoming meetings: the Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and the Parent Project Muscular Dystrophy 25th Annual Conference.
- Zacks•last month
Vertex Expands Collaboration With CRISPR, Acquires Exonics
Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CATB earnings conference call or presentation 14-May-19 12:30pm GMT
Q1 2019 Catabasis Pharmaceuticals Inc Earnings Call
- GuruFocus.com•2 months ago
SV Life Sciences Advisers, LLC Buys Catabasis Pharmaceuticals Inc, Sells KalVista ...
Boston, MA, based Investment company SV Life Sciences Advisers, LLC buys Catabasis Pharmaceuticals Inc, sells KalVista Pharmaceuticals Inc, Avrobio Inc during the 3-months ended 2019Q1, according to the ...
- Business Wire•2 months ago
Catabasis Pharmaceuticals Reports First Quarter 2019 Financial Results and Reviews Business Progress
-- Edasalonexent Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Enrolling Boys Globally --
- Business Wire•3 months ago
Catabasis Pharmaceuticals to Present Data from the MoveDMD® trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced that it will present data on edasalonexent treatment in boys affected by Duchenne muscular dystrophy (DMD) from the MoveDMD trial open-label extension at the American Academy of Neurology 71st Annual Meeting to be held May 4 to May 10, 2019 in Philadelphia, PA. Richard Finkel, M.D., Chief, Division of Neurology, Department of Pediatrics at Nemours Children’s Health System and a Principal Investigator for the Phase 2 MoveDMD and Phase 3 PolarisDMD studies of edasalonexent, will give an oral presentation titled “Edasalonexent, an NF-kB Inhibitor, Slows Longer-Term Disease Progression on Multiple Functional and MRI Assessments Compared to Control Period in 4 to 7 Year-Old Patients with Duchenne Muscular Dystrophy” during the S51 session “Child Neurology: Bench to Bedside: Progress in Treating Genetic Disorders” on Thursday, May 9 at 4:25pm ET.
- Business Wire•3 months ago
Catabasis Pharmaceuticals to Report First Quarter 2019 Financial Results and Recent Corporate Developments on Tuesday, May 14th
The company will host a conference call at 8:30am ET
- Simply Wall St.•3 months ago
Should You Be Concerned About Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) Historical Volatility?
Anyone researching Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of...
- Zacks•3 months ago
Top Ranked Momentum Stocks to Buy for April 12th
Top Ranked Momentum Stocks to Buy for April 12th
- Business Wire•4 months ago
Catabasis Pharmaceuticals to Present at Upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent program data, including from the Phase 2 MoveDMD trial and open-label extension, and the design of the Phase 3 PolarisDMD trial, at two major medical meetings in April: the 12th UK Neuromuscular Translational Research Conference and the 2019 Muscular Dystrophy Association ...
- Zacks•4 months ago
Proteostasis Plunges on Weak Data From Cystic Fibrosis Study
Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.
- Zacks•4 months ago
Will Catabasis Pharmaceuticals Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Catabasis.
- Zacks•4 months ago
Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight
Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight
- Zacks•4 months ago
Rising P/E an Overlooked Criterion: 5 Top Stocks
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratio.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of CATB earnings conference call or presentation 14-Mar-19 12:30pm GMT
Q4 2018 Catabasis Pharmaceuticals Inc Earnings Call
- Zacks•4 months ago
Catabasis (CATB) Beats Earnings in Q4, Revenues Nil
Catabasis (CATB) beats earnings estimates in the fourth quarter of 2018. The company has no revenues. Shares up.
- Business Wire•4 months ago
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Reviews Business Progress
-- Edasalonexent Phase 3 PolarisDMD Trial Globally Enrolling Boys with Duchenne Muscular Dystrophy --
- Business Wire•4 months ago
Catabasis Pharmaceuticals to Present at Oppenheimer’s 29th Annual Healthcare Conference
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 at 8:00am ET at the Westin New York Grand Central Hotel in New York City, NY.
- Zacks•4 months ago
Townsquare (TSQ) to Report Q4 Earnings: What's in the Cards?
Townsquare's (TSQ) fourth-quarter 2018 results are expected to benefit from higher political revenues.
- Zacks•4 months ago
Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
- Zacks•4 months ago
Is a Beat in Store for Catabasis (CATB) This Earnings Season?
Catabasis (CATB) progresses with DMD candidate, edasalonexent. However, operating expenses are likely to be lower.
- Simply Wall St.•4 months ago
Investors Who Bought Catabasis Pharmaceuticals Shares Three Years Ago Are Now Down 93%
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So take a moment to sympathizeRead More...
